View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Research Reports
April 28, 2017

Licensing deals in Duchenne Muscular Dystrophy (DMD)

On 13 April 2017, Roche entered a licensing agreement with Bristol Myers Squibb (BMS) for the license of the anti-myostatin adnectin BMS-986089.

By GlobalData Healthcare

On 13 April 2017, Roche entered a licensing agreement with Bristol Myers Squibb (BMS) for the license of the anti-myostatin adnectin BMS-986089.

The agreement meant Roche would pay BMS an upfront payment of $170 million with the potential of milestone payment of $205 million. Biogen have also entered a licensing agreement with BMS for the anti-eTau compound which is phase II ready for potential in Alzheimer’s Disease and progressive supranuclear palsy (PSP). Licensing assets to both Biogen and Roche means that BMS will be able to prioritise other potential opportunities for asset development for their portfolio.

Figure 1 shows a comparable number between licensing and partnership deals within Duchenne Muscular Dystrophy.

However, figure 2 shows over the last five years a growth in the number of licensing deals occurring in the Duchenne Muscular Dystrophy space year by year meaning this is a strong area providing companies with opportunities for asset development for the future.

 

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology